As of its latest 13F filing with the Securities and Exchange Commission, Armor Investment Advisors LLC increased its position in Johnson & Johnson by 8.0% during the fourth quarter. Institutional investors now own 14,318 shares in the company after purchasing an additional 1,060 shares during this period. This increase in holdings brings Johnson & Johnson to approximately 1.5% of Armor Investment Advisors LLC’s investment portfolio, making it the 21st largest position. Their latest filing shows their holding in Johnson & Johnson was worth a staggering $2,529,000 at the end of the most recent reporting period.
Johnson & Johnson is a well-known holding company engaged in the research and development, manufacturing and marketing of products for the healthcare sector. The company operates in his three main segments: consumer health, pharmaceuticals and medical technology. The Consumer Health segment includes a broad range of personal health care products focused on the skin health/beauty, over-the-counter, baby care, oral care, women’s health and wound care markets.
Stakeholders are aware of insider trading activity. James D. Swanson, a senior internal executive, sold back more than 1,000 shares of Johnson & Johnson stock at an average of $154.66 per share on Monday, March 6. The total transaction value is $164,248.92. He currently owns only about 9,200 shares worth about $1.4 million, according to post-deal disclosures.
These recent news are a sign of these important changes as November approaches and we are rapidly approaching the date of JOhnson & Johnson’s next earnings report, scheduled for late October with much hope. is fueling investor excitement as they try to determine what it means for this giant player in the healthcare industry. Good news based on these moves based on stock trading by insiders such as James D. Swanson and an increase by institutional investors such as Armor Investment Advisors LLC.
Despite Market Volatility, Investors Show Confidence in Johnson & Johnson’s Growth Potential
Johnson & Johnson, one of the world’s leading healthcare companies, has seen several large investors change their stakes in recent months. Curated Wealth Partners LLC increased its holdings by 7.6% in the fourth quarter, and Baron Silver Stevens Financial Advisors LLC purchased new shares of Johnson & Johnson during the same period. It has also received similar funding from Howland Capital Management, McLaren Financial Advisors and Berger Financial Group. Research firms have commented on the company in various reports, with UBS Group starting reporting with a ‘neutral’ rating and Cantor Fitzgerald rating it ‘overweight’. Seven investment analysts gave hold ratings, six issued buy ratings, and one gave a strong buy designation.
Johnson & Johnson is divided into three segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment manufactures personal health care products for the skin health/beauty, over-the-counter, baby care, oral care, women’s health, and wound care markets.
The company maintains steady growth despite all sorts of fluctuations in global economic conditions. Currently valued at more than $400 billion in market capitalization and operating under the NYSE (New York Stock Exchange) ticker symbol JNJ, JNJ opened today at $161.01 per share, with a P/E ratio of was 23.89 and the beta value was 0.53.
The company recently released impressive numbers for the first quarter of 2023, with earnings per share of $2.68 for the quarter, beating expectations by about $0.17 per share. Additionally, reported earnings exceeded analyst expectations of $23.61 billion for him by $24.75 billion.
Overall data suggests there is still room for cautious optimism among investors as the stock is still viewed as having future growth potential.